Hepatocellular Carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. Current systemic therapies result only in modest benefits and new therapeutic options are critically needed. Some patients show promising clinical responses to immune checkpoint inhibitors, however, additional immunotherapeutic approaches, such as adoptive cell therapies (ACT), need to be developed. This review summarizes recent ACT studies and discusses the promise and obstacles of this approach. We further discuss ways of improving the efficacy of ACT in HCC including the use of combination therapies and locoregional delivery methods.

中文翻译：

---

过继性细胞免疫疗法治疗肝细胞癌的前景。

肝细胞癌（HCC）是全球癌症相关死亡的主要原因之一。目前的全身疗法仅产生有限的益处，因此迫切需要新的治疗选择。一些患者对免疫检查点抑制剂表现出有希望的临床反应，然而，需要开发其他免疫治疗方法，例如过继细胞疗法（ACT）。这篇综述总结了最近的 ACT 研究，并讨论了这种方法的前景和障碍。我们进一步讨论了提高 ACT 在 HCC 中疗效的方法，包括使用联合疗法和局部给药方法。